Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

May 11, 2023

NASDAQ US Health Care Biotechnology earnings 23 min

Earnings Call Speaker Segments

Craig Collard

executive
#1

Thanks, operator. Hello, everyone, and good afternoon. You're joining us for Heron Therapeutics' First Quarter 2023 Earnings Call. I'm Craig Collard, Heron Therapeutics' new CEO, and I'm very excited to be heading up this company as we keep building momentum in the hospital and oncology markets. Today, I'll give an overview of how we've performed recently, point out some key accomplishments, but more importantly, share some thoughts from my assessment of the business during my first 4 weeks and talk about where we're headed strategically. First quarter total product net revenues came in at $29.6 million, compared with $23.5 million during last year's same quarter — a rise of over 26%. On the oncology side of our business, we keep making steady progress, though we're still enthusiastic about the market opportunity for both ZYNRELEF and APONVIE, our newly approved product, which launched in March of this year. Beginning with ZYNRELEF, I recognize that since launch, this product has had a slow uptake for a number of reasons. Even though it competes in a massive market, the product has a differentiated clinical profile that performs well when it's used. Our label has restricted our ability to become the drug of choice across many indications. To address that, we submitted an sNDA with an October 23 PDUFA date that, should it be approved, would broaden our indications and the number of procedures we can treat. Because our product is viscous, withdrawal from the vial has been slower relative to other drugs. To make handling better, we recently kicked off multiple enhancement programs aimed at some of the problems we've encountered in the surgery suite during preparation, including a vial access needle, or van, and eventually a prefilled syringe that could be game changing. Since I joined the company, I've managed to get out in the field and work alongside our sales representatives, which I always find useful when trying to evaluate product performance issues. I'm glad to say that thus far, I have watched ZYNRELEF being used in 5 knee surgeries. I was trying to figure out what actually happens when the product is applied. Before, I'd heard conflicting reports regarding how long it takes to draw the product out of the vial, product viscosity and general problems that would make using our product harder. What I concluded from observing these surgeries is that we can replicate the success I witnessed in this day. Application calls for training the staff since it is different, but not complex. The nursing staff even acknowledged that after a few uses of the product, it became second nature and is now simply part of the normal routine and prep before the surgeon arrives. I believe that early in the product's launch, our company failed to tackle this issue directly and didn't grasp that this was going to require more training of our reps and shone a light on our own inefficiencies. Every product tends to face hurdles right after it hits the market, and typically the businesses that have done their homework and can act fast end up winning in the end. On the positive side, there's still time to correct course with this launch; let's turn to APONVIE now. That product came to market 1 month before I came on board. APONVIE, an injectable emulsion, holds the distinction of being the sole IV substance NK1 receptor antagonist approved for postoperative nausea and vomiting. Just like ZYNRELEF, it's a product boasting a strong clinical profile along with marketing advantages, and it plays in an extremely big market. Our belief is that APONVIE is going to be a highly successful item within our portfolio, and it offers substantial call point overlap in relief. Though the response to the initial launch is encouraging, we'll seek out ways to get the most from this potential and keep our shareholders updated as we make progress over the course of this year. Before I hand the call to David for a financial review, I figured it could be useful to share some perspective on the business overall and offer a view into where we're heading strategically going forward. Since I came aboard, I've devoted a lot of my time to grasping each department's headcount spin and how the company operates as a single unit. The aim has been to conduct a comprehensive internal review to figure out the company's business practices and strategies, so we can craft a long-term plan that lets the company maximize value for every shareholder. My review isn't finished yet, but I can share that I now understand the company far better, and numerous changes are on the way soon, among them a cut in cash burn, gains in operational efficiency, and the rollout of a realistic product forecast to pin down our capital requirements more accurately going forward. Not long after I came aboard, I put the first big change into place, which was flattening the executive reporting structure across the company. I brought on Jason Grillot, someone I've worked with before, to head our sales and marketing efforts. Jason is going to improve a lot of things within the commercial structure, such as targeting, alignment, accounting support, marketing message and data to the sales force, and management reporting. My belief is that these changes, plus many others I'll update later, will keep boosting the uptake of our products. Additional expense cuts we'll be making include reduced outsourcing and reliance on consultants, as well as a decrease in headcount. Once again, I'll share more specifics in the near future. As you're aware, I've been evaluating every facet of our business to make sure we're well positioned for what's ahead. I realize this process might be creating some uncertainty and worry among our shareholders. We're dedicated to giving you as much information as we can regarding the strategic direction changes that are coming. We get that you've put your time and resources into our company, and we appreciate your input and support. Our aim is to keep everyone updated at each stage while we move through this process. Soon we intend to provide additional specifics regarding the adjustments we'll make and what motivates them. Building a company that's stronger and more sustainable—one better suited to serving what our customers and stakeholders need—is what we're after. Thank you for your patience and understanding while we carry out this work; we trust these changes will set us up for success over the long term, and we're eager to bring you further updates shortly. David, please go ahead.

David Szekeres

executive
#2

Thanks, Craig. Craig mentioned this in his remarks, and to build on that: for the first quarter of 2023, net product sales were $29.6 million. In the first quarter of 2022, that figure was $23.5 million. So compared with the same period in 2022, that represents a 26% increase. When it comes to ZYNRELEF, sales hit $3.5 million during the first quarter of 2023. APONVIE launched commercially in the U.S. in March 2023, and APONVIE net product sales for the first quarter of 2023 added up to $244,000. During Q1, net product sales from our Oncology Care franchise came to $25.8 million, which is 15% higher than what we saw in the same quarter last year. Looking ahead to the full year 2023, we're projecting net product sales for the Oncology Care franchise between $99 million and $103 million. Turning to cost of product sales, Q1 2023 came in at $16.9 million versus $11.4 million during the comparable period in 2022. Within that Q1 2023 figure, there was a onetime charge of $5.3 million, driven mainly by writing off short-dated ZYNRELEF inventory. On the R&D side, expenses went from $42.1 million in Q1 2022 down to $13.8 million in the first quarter of 2023. The main driver there was lower external development costs tied to ZYNRELEF. Sales and marketing came in at $21.2 million for the first quarter of 2023, a modest decline from $23.4 million in Q1 2022, largely because we spent less supporting the ongoing commercialization of ZYNRELEF. For the first quarter of 2023, our loss from operations was $33.1 million, compared with an operating loss of $62.9 million in Q1 2022. Looking at where we stood at the close of March 2023, the cash position came in at $60 million, which is a decline from the $84.9 million we had on the books at the end of December 2022. Craig, I'll hand it back over to you.

Brandon Folkes

analyst
#3

Congrats on the new role. First off, from my side, how soon do you figure we might see a payoff from the way staff are being traded? Second, I realize it's still early days and we probably ought to stay a bit patient. Still, any additional detail about moving forward and getting deeper into those accounts, plus perhaps some of the particular things you believe you can do to alter ZYNRELEF's trajectory? And last, some context — I know this wasn't given while you were around, Craig — but my recollection is that during our year-end earnings report, we projected first-quarter 2023 volume would rise 10% compared with the fourth quarter of 2022. So, any detail would help: did that increase in volume materialize? Did pricing shift at all? Just anything you can share regarding ZYNRELEF.

Craig Collard

executive
#4

I'd likely start by pointing out that, as you know, we're focused on conserving cash. Our real goal here is getting the most out of what we have. As for the share price and things like that, my view is that once property management keeps delivering steady quarters and our product keeps expanding, that should, again, shape where the stock goes over a longer horizon. In the near term, though, keep in mind that I wasn't around for the quarter I'm talking about. So on product growth, that kind of thing, and account depth, and what happened last quarter — I can't speak to any of that. All I can do is speak to where we stand right now. To circle back, though — the goal here is getting the business profitable as quickly as possible. We'll share far more specifics on how we do that, and honestly that involves a number of medications within our cost structure, plus running things with a slimmer team overall and truly getting the most out of our sales efforts. On ZYNRELEF in particular, and going further into accounts and those types of things — yes, I'm with you, wherever we've got usage, there's clearly room to go further into those accounts. I mentioned briefly the time I spent out in the field; and the main takeaway from that experience was that I'm looking for anything we're able to standardize. The point someone might overlook is whether you can actually get all of your sales reps to adopt it and build something repeatable. Once I looked at that data, I believe we can, and as for the application problems I've both witnessed and been told about, like I mentioned, solid preparation and training make them disappear. That day, when the surgeon came in for the knee procedure, it was completely unnoticeable to him. They actually used it while the operation was underway — inside what you'd call the sterile field. And one detail we brought up that struck me as quite interesting, since we've discussed best cost extensively, is that the surgeon told me he's a big fan of best cost and even referred to the product as honey. His words were, "What I really appreciate about the best cost of this product is that it remains right where I place it. And once again, in some respects, I feel we kind of retreated from that, but my view is that we ought to be moving toward it." My honest belief is that this product has a great deal of room for optimization. And to repeat, the encouraging part is that it does work, and it performs effectively.

Boris Peaker

analyst
#5

Nick here, filling in for Boris. Just a quick one regarding APONVIE. What's your thinking on how to take this to market going forward? I know you said there are plenty of parallels between the calls you'd be making for APONVIE and those for ZYNRELEF. But I was wondering, setting that aside, how you'd plan to sell this in a way that could drive quicker growth in ZYNRELEF?

Craig Collard

executive
#6

Yeah. No, that's a terrific question. I mean, one thing I kind of ran into when I came into the company was the question of where your resources go. Do you keep directing additional resources at ZYNRELEF? Or do you shift things somewhat more in the direction of APONVIE? My sense is that right now, when I arrived, we leaned a bit more heavily toward ZYNRELEF. And when you think it through, ZYNRELEF is a more difficult cell. More time and effort get spent on the surgeon and in the surgery suite. APONVIE is somewhat different. It's nearly like an annuity. In a way, if you're getting formula — if you can get through P&T and land on formulary, you wind up almost in a protocol type of situation where you're inside the epic system and you're being used constantly. So from where I sit, APONVIE is a far simpler sell; then again, how customers have responded to it and all of that. I simply haven't had the opportunity to actually observe much of that so far; but as part of this kind of plan, as I mentioned around communicating more going forward, we're examining that, and we're aiming to commit additional resources behind APONVIE. The genuinely fascinating thing I've observed from the marketing data up to this point and upon though is that the oral prepatent market is expanding with absolutely no promotion, and that's typically under — and so what you take from that is hospitals and physicians and anesthesiologists are fond of this product, and it's growing with absolutely zero promotions; so if I consider that and then I consider the enormous size of the damage market and really just consider patients who get dosed again with the same product, if we could merely capture those 2 markets, I mean, this is a multi-hundred million dollar drug. And so seen that way, it truly doesn't treat you of what we can actually do with that product; so again, we're examining it now and attempting to really consider not just how we comp our reps, but the alignment of our sales force and all of that. So I think all of that remains up in the air at this point, but we'll have some decisions here pretty quickly.

Boris Peaker

analyst
#7

All right. So regarding the VAN in a prefilled syringe, what steps come next in order to secure approval for those? And what's your expected timing for that happening with each one?

Craig Collard

executive
#8

Apologies — did you mean the prefilled syringe?

Boris Peaker

analyst
#9

And the VA too...

Craig Collard

executive
#10

Yeah, so — there are a few preliminary schedules I've reviewed. My hope is that we can move a bit faster on this, but it's — and we've already put in some effort on the prefilled syringe; so I mean, what I've generally been hearing is that we're roughly targeting the 26th as the timeframe, though I'd like to see us shorten that somewhat. The van will likely land at some point within that window. So should things play out that way, the VAN would arrive in roughly 1.5 years, and then, say, 1.5 years after that you'd have the prefilled syringe. And I believe amid all of that, you've also potentially got the label expansion through the sNDA filing.

Rohit Bhasin

analyst
#11

Rohit here, sitting in for Serge. About the CINV franchise — the earlier leadership team had put out a forecast of $99 million to $103 million. Is that forecast still valid? And second, you brought up lowering cash burn. Are there any plans to scale back the sales force?

Craig Collard

executive
#12

Yes. So, starting with the CINV franchise. I'm aware that guidance was provided previously. What I can say is that, in my view, the CINV franchise is progressing pretty well and is relatively stable. What bothered me when I first looked at it — to be completely candid, I've never been part of a company that issued guidance on only some products. So, once we get our arms around this, what I'd rather do is provide guidance more from a company standpoint and less focused on any single product. That's roughly the rationale, and it was my call. But I can tell you that things are progressing fairly steadily. As for — I'm trying to recall the other part of what you asked.

Rohit Bhasin

analyst
#13

Right. So you brought up cutting down how much cash we're burning. Is there anything planned when it comes to the sales team?

Craig Collard

executive
#14

Yeah, apologies — the sales team. That's something we're evaluating. Like I said, our goal is greater efficiency. It might end up being more about realigning things. On the oncology side, we are definitely not making any changes. On the acute side, I think what we're doing is genuinely trying to figure out whether we're matched up with the right accounts and what that situation looks like. Might we scale it back somewhat near term? That could happen, but honestly our focus is more on how to better line things up with the — whether that's APONVIE, ZYNRELEF and the way we approach it. So it's — that requires some time. And Jason, as I said earlier, came on board only a few weeks back and he's fully engaged with it. So my hope is that we'll be able to share something clearer on this before long.

Carl Byrnes

analyst
#15

Nice work on the promotion. Thinking about that one-time ZYNRELEF inventory write-off — I believe the figure mentioned was $5.3 million. If we take that out, the gross profit margin appears to have come in at approximately 61%. Is that accurate? And would you consider that level sustainable, both for the second and looking ahead to upcoming quarters?

Craig Collard

executive
#16

Yes. Carl, that's a terrific question. You offered congratulations on my promotion just now. My hope is that in the next quarter, or the quarters that follow, what you'll be saying is, hey, guys, congratulations on a great quarter. That's the goal we're working toward. So I wanted to mention that first, I suppose. As for gross margin, no, we're clearly not where we need to be. I'd like to see us progress toward a COGS below roughly 20%, which would mean 80% gross margins; that's the target I'm aiming for. And I believe with what we're doing on batch size, you're going to start seeing some of that show up now. I'm also reviewing every manufacturing agreement we have to find where improvements can be made. So ideally, I want to bring us down into what I'd describe as the high teens to 20% range. So we aren't there yet, but obviously this one-time ZYNRELEF write-off had an impact.

Kelly Shi

analyst
#17

This is Clara, filling in for Kelly. Regarding the accounts you're going after for APONVIE and ZYNRELEF, what strategy would you use to get the most out of having those 2 products together? And how do you expect that synergy to show up in sales across the next few quarters? Also, on the sNDA for ZYNRELEF, what strategies and efforts are in place to help everyone see the extra opportunity that this added indication points to?

Craig Collard

executive
#18

Yes. Thanks for asking. Let me begin with the sNDA. As you're aware, we submitted it to the FDA, and a PDUFA date exists; beyond that, though, there's no way for us to forecast which indications we'll secure or how wide the label will end up being approved for; our hope, clearly, is that it widens and we receive every indication we've requested, yet we simply don't have that knowledge at this point. That makes planning hard until you truly understand what you'll end up with; so expect more updates later. As for APONVIE and ZYNRELEF, the synergies between them — if you stop and think, these are 2 products that pair up extremely well. What we're genuinely wrestling with today is deciding where our resources should go. When I consider ZYNRELEF and think about a van coming, there's a potential sNDA expansion, and then there's the prefilled syringe, which ought to be truly transformative since it resolves the entire sterility issue; so someone could make the case that during this stretch, we ought to direct more resources perhaps toward APONVIE, which sells more easily and faster and carries something of an annuity quality within a very sizable market. Once more, I lack specifics right now, but that's the debate we're having. I believe we'll have answers quite soon; the encouraging part is that these products, as you noted, do pair up well. Their call points overlap. And over time, I believe both should expand considerably; the only issue is which one we prioritize first and how we go about that.

Craig Collard

executive
#19

Absolutely. Thanks, operator. To start, I want to express my appreciation to everybody on this, my initial call since becoming Heron's CEO. I also genuinely want to give thanks to the entire staff here. Change isn't easy, after all. Once again, quite a few things have been happening around here, and we're in the process of assembling a great deal of information; and I believe what lies ahead for you to observe is a company that looks vastly, vastly different, one that, once again, will move in the direction of profitability and will achieve success. So that makes me enthusiastic. And once more, I simply want to thank each person here who has been involved in this so far. We'll be with you again next quarter.

Operator

operator
#20

Everyone, we've reached the end of today's call. Thanks to each of you for being here. You can go ahead and disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.